help button home button
AJRCMB
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Published ahead of print on April 21, 2005, doi:10.1165/rcmb.2005-0100OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2005-0100OCv1
33/1/105    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peek, E. J.
Right arrow Articles by Hawrylowicz, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peek, E. J.
Right arrow Articles by Hawrylowicz, C. M.
American Journal of Respiratory Cell and Molecular Biology. Vol. 33, pp. 105-111, 2005
© 2005 American Thoracic Society
DOI: 10.1165/rcmb.2005-0100OC

Interleukin-10–Secreting "Regulatory" T Cells Induced by Glucocorticoids and ß2-Agonists

Emma J. Peek, David F. Richards, Alexander Faith, Paul Lavender, Tak H. Lee, Christopher J. Corrigan and Catherine M. Hawrylowicz

Department of Asthma, Allergy and Respiratory Science, GKT School of Medicine, King's College London, Guy's Hospital, London, United Kingdom

Correspondence and requests for reprints should be addressed to Dr. Catherine M. Hawrylowicz, Department of Asthma, Allergy and Respiratory Science, 5th Floor Thomas Guy House, GKT School of Medicine, King's College London, Guy's Hospital, London SE1 9RT, UK. E-mail: catherine.hawrylowicz{at}kcl.ac.uk

Greater clinical benefit in controlling the symptoms of asthma is frequently observed through combining moderate doses of inhaled glucocorticoids together with long-acting ß2-agonists, as compared with increasing glucocorticoid dosage alone. To address in vitro whether glucocorticoids plus ß2-agonists, compared with glucocorticoids alone, have greater inhibitory activity on CD4+ T cell responses to allergen, peripheral blood CD4+ T cell responses to allergen were compared in the presence or absence of the glucocorticoid fluticasone proprionate and the short- and long-acting ß2-agonists salbutamol and salmeterol, respectively. Fluticasone proprionate inhibited interleukin (IL)-5 and IL-13 and enhanced IL-10 synthesis in allergen-stimulated cultures in a concentration-dependent manner. Salmeterol, but not salbutamol, inhibited IL-5 and IL-13 and enhanced IL-10 synthesis in these cultures. When used in combination the two drugs demonstrated an additive effect on this pattern of cytokine production. Allergen-specific T cell lines induced in the presence of salmeterol and fluticasone proprionate inhibited IL-5 and IL-13 production by allergen-specific Th2 cell lines in an IL-10–dependent manner. Thus fluticasone proprionate and salmeterol increased IL-10 and reduced Th2 cytokine synthesis additively in allergen stimulated human CD4+ T cells.

Key Words: interleukin-10 • glucocorticoids • ß2-agonists • regulatory T cells




This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
K. D. Nguyen, C. Vanichsarn, and K. C. Nadeau
Impaired IL-10-dependent Induction of Tolerogenic Dendritic Cells by CD4+CD25hiCD127lo/- Natural Regulatory T Cells in Human Allergic Asthma
Am. J. Respir. Crit. Care Med., November 1, 2009; 180(9): 823 - 833.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
F. Meiler, J. Zumkehr, S. Klunker, B. Ruckert, C. A. Akdis, and M. Akdis
In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure
J. Exp. Med., November 24, 2008; 205(12): 2887 - 2898.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Crit. Care Med.
Copyright © 2005 American Thoracic Society. 		  Membership Renewal